Data from T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab

التفاصيل البيبلوغرافية
العنوان: Data from T Cells in Tumors and Blood Predict Outcome in Follicular Lymphoma Treated with Rituximab
المؤلفون: Eva Kimby, Birger Christensson, Birgitta Sander, Anne M. Tierens, Martin Maisenhölder, Tuula Lehtinen, Peter de Nully Brown, Christian H. Geisler, Bjørn Østenstad, Marie Nordström, Ola Lindén, Herman Nilsson-Ehle, Martin Erlanson, Hans Hagberg, Harald Holte, Christer Sundström, Björn Engelbrekt Wahlin
بيانات النشر: American Association for Cancer Research (AACR), 2023.
سنة النشر: 2023
الوصف: Purpose: T cells influence outcome in follicular lymphoma, but their contributions seem to be modified by therapy. Their impact in patients receiving rituximab without chemotherapy is unknown.Experimental Design: Using flow cytometry, we evaluated the T cells in tumors and/or blood in a total of 250 follicular lymphoma patients included in two Nordic Lymphoma Group randomized trials that compared single rituximab with IFN-α2a–rituximab combinations.Results: In univariate analysis, higher levels of CD3+, CD4+, and CD8+ T cells in both tumors and blood correlated with superior treatment responses, and in multivariate analysis, tumor-CD3+ (P = 0.011) and blood-CD4+ (P = 0.029) cells were independent. CD4+ cells were favorable regardless of treatment arm, but CD8+ cells were favorable only in patients treated with single rituximab, because IFN-α2a improved responses especially in patients with low CD8+ cell levels. Higher levels of blood-CD3+ (P = 0.003) and blood-CD4+ (P = 0.046) cells predicted longer overall survival, and higher levels of blood-CD8+ cells longer times to next treatment (P = 0.046).Conclusions: We conclude that therapeutic effects of rituximab are augmented by tumor-associated T cells for rapid responses and by systemic T cells for sustained responses. CD4+ and CD8+ cells are both favorable in patients treated with rituximab. IFN-α2a abrogates the negative impact of few CD8+ cells. Clin Cancer Res; 17(12); 4136–44. ©2011 AACR.
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::457bdc64c63055afde578b47747904b0Test
https://doi.org/10.1158/1078-0432.c.6518275Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....457bdc64c63055afde578b47747904b0
قاعدة البيانات: OpenAIRE